Determinants of Medication Use in Diabetes Results from a Large Database of Pharmacy Complaints

Rph. Saad Ali Al Arfaj [1*], Rph. Mohammed Khalid Al Rabiah[2], Rph. Ismail Haider Baqtayyan[3]

[1]Corresponding Author, Pharmacy Department, King Abdulaziz medical city in Riyadh Ministry of National Guard
[2]Pharmacy Department, King Abdulaziz medical city in Riyadh Ministry of National Guard
[3]Pharmacy Department, King Abdulaziz medical city in Riyadh Ministry of National Guard

Paper Publication Date: 5th June 2016

Abstract:
Background: Diabetes mellitus has become a global epidemic, with an increase in prevalence worldwide.

Methods: Adherence to treatment necessitates that the individual undergo routine clinical examinations on a regular basis, complete the treatment programme, use the medications on a regular and proper basis, and adopt the proposed behavioral changes.

Results: Patients benefit greatly from chemists' education on medication management, diet control, and self-management.

Conclusion: Identifying factors related to medication awareness is thus an important first step towards improving medication adherence.

Keywords: Diabetes, medication adherence, medication management, Database of Pharmacy Complaints

Introduction

Diabetes mellitus has become a global epidemic in recent decades, with an increase in prevalence worldwide. Diabetes necessitates sufferers' self-motivation to adhere to a lifelong combination of pharmacological and non-pharmacological therapy; thus, patient adherence to treatment is required. The combination aims to reduce the risk factors for the disease's micro and macro vascular consequences. Adherence to combination therapy is critical in diabetes treatment, but it has received insufficient attention from clinicians. Diabetes therapy is also dependent on the patient's self-management, but therapy failure is frequently caused by non-adherence to treatment. Such behaviour is a major impediment to the successful treatment of this disease.[1]

Diabetes necessitates sufferers' self-motivation to adhere to a lifelong combination of pharmacological and no pharmacological therapy; thus, patient adherence to treatment is required. The combination aims to

reduce the risk factors for the disease's micro and macro vascular consequences. Adherence to combination therapy is critical in diabetes treatment, but it has received insufficient attention from clinicians.[2]

Diabetes therapy is also dependent on the patient's self-management, but therapy failure is frequently caused by nonadherent treatment behaviour. Such behaviour is a major impediment to the successful treatment of this disease.

Diabetes care is fundamentally concerned with promoting healthy behaviours through medical nutrition therapy (MNT), physical activity, and psychological support, as well as weight management and tobacco/substance abuse counselling, as needed. This is frequently provided as part of diabetes self-management education and support (DSMES). The growing number of glucose-lowering interventions—from behavioural interventions to pharmacological interventions, devices, and surgery—as well as growing information about their benefits and risks give people with diabetes and providers more options, but also complicate decision-making.[3] The demonstrated benefits of glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) for high-risk individuals with atherosclerotic cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) provide significant progress in treatment aimed at reducing the progression and burden of diabetes and its complications. These advantages are largely unrelated to their glucose-lowering properties. These treatments were initially introduced as glucose-lowering agents, but they are now also used to protect organs. [4]

2. Literature review

Diabetes is defined as a fasting or postprandial hyperglycemic state. Chronic hyperglycemia in diabetes mellitus (DM) is linked to end organ damage, dysfunction, and failure in organs and tissues such as the retina, kidney, nerves, heart, and blood vessels. [5]
Although the vast majority of diabetes cases fall into the two broad etiopathogenetic categories of type 1 and type 2 diabetes, this rigid classification does not apply to all patients.[6]

2.1 Causes of diabetes:

Type 1 diabetes has an autoimmune basis and is caused by a complete lack of insulin. Until the etiology of diabetes mellitus was reclassified, this disorder was known as insulin-dependent diabetes mellitus (IDDM). The disorder is distinguished by immune-mediated b cell destruction, and hyperglycemia occurs only after 90% of b cells have been lost.
The most common type of diabetes, accounting for 90-95% of cases, is type 2 diabetes. It is caused by a relative insulin deficiency, but the primary flaw is insulin resistance. [7]
Gestational diabetes is defined as carbohydrate intolerance that begins or becomes apparent during pregnancy. Diabetes mellitus (type 1 or type 2) that was previously undiagnosed may manifest, particularly during initial pregnancy evaluations. Gestational diabetes, on the other hand, is treated separately from type 2 diabetes. Increased insulin resistance necessitates the use of more insulin as the pregnancy progresses. In order to obtain relevant information for management, a brief clinical history should be obtained. As previously stated, the mnemonic Diagnosis, Control, Complications, Teachable Issues (DCCT) from the landmark study can help with an organised assessment. [8]

Adherence to treatment is defined as the patient's acceptance and adherence to health-related recommendations. This adherence necessitates that the individual undergo routine clinical examinations on

a regular basis, complete the treatment programme, use the medications on a regular and proper basis, and adopt the proposed behavioural changes.[9]

Nonadherence to treatment and low health literacy are linked to a lack of understanding of treatment methods, an increase in medication usage errors, a lack of access to health services, a decrease in early screening frequency, a decline in quality of life, and thus high morbidity and mortality rates. Furthermore, by increasing hospitalisation rates and utilising high-cost services, such as emergency services, this situation raises the cost of health care. [10]

Individuals with diabetes are typically seen by multidisciplinary health-care teams in the public sector, which include physicians, nurses, dieticians, and pharmacists working in diabetic clinics. In such cases, the chemist on the team assists with medication counselling and evaluates patients' medication adherence.[11]
Patients must have disease-related knowledge and decision-making skills in order to practise good self-care and disease management. Diabetes management has been reported to be poor in patients with poor diabetes knowledge.[12]

Numerous studies have found that pharmacist education can help improve patients' knowledge of disease, resulting in better clinical outcomes. However, such studies are frequently conducted in a controlled environment (hospitals or primary health-care centres), and little is known about chemists' roles in medicine management outside of clinical settings. [13]

Previous research has linked anti-diabetic medication storage to non-adherence and insulin instability, which leads to sub-glycemic control. Furthermore, adherence to good storage conditions of antidiabetic medications is dependent on DM patients' level of knowledge and awareness of medication storage.[14]

3. Methodology

The work of chemists in clinical settings is one possible method of providing patients with disease-related knowledge. Pharmacists play an important role in educating patients about medication management, diet control, and self-management. [15]

HbA1c > 6.5 has been reported in diabetic patients.
High adherence (score = 8), medium adherence (score = 6-7), and low adherence (score = 6) were assigned. Patients with medium and low adherence ratings were classified as non-adherent. [16]

3.1 Data collection:

Pre-intervention baseline assessment of diabetes-related knowledge and medication adherence by pharmacy complaints.

4. Results

Well-designed interventions can be effective at changing beliefs and attitudes, potentially leading to population-wide behaviour change.

For noncritically ill patients treated with insulin, the premeal (fasting)capillary blood glucose goal should be 140 mg/dL (7.8 mmol/L), with random blood glucose values of 80 mg/dL (10.0 mmol/L), if these targets can be safely met.

Regular scheduled subcutaneous insulin administration is the preferred method for achieving and maintaining glucose control.[17]

Despite the fact that intensive insulin therapy was previously widely used in the acute stroke setting, clinical data supporting a euglycemic approach is lacking due to the associated proclivity for hypoglycemia, which results in higher mortality.
Patient education is an important tool in this situation for improving medication adherence and diabetes management.[18]

5. Discussion

According to the International Diabetes Federation (IDF), more than 425 million people worldwide have diabetes mellitus (DM).
Disparities in the region's diabetic patients' population, ethnicity, culture, and socioeconomic status allow for differences in the determinants of medication adherence.[19]
Healthcare professionals, particularly chemists, play a critical role in developing strategies to improve medication adherence so that patients can optimise diabetes treatment and limit diabetes progression. This emphasises the importance of patient education and medication awareness after becoming aware of DM. As a result, the first step for healthcare providers could be to raise DM medication awareness.[20]

6. Conclusion:

Patients who understood and were aware of their diabetic medication performed better in terms of glucose control and medication adherence. Identifying factors related to medication awareness is thus an important first step towards improving medication adherence.
The Pharmacy Complaints Database tracks blood glucose levels, prioritises patient satisfaction by ensuring that they receive appropriate care, and fosters a respectful and caring relationship with patients by involving them in decision-making. Patient education can be improved by first determining the individual's learning needs and then providing them with tailored educational interventions to meet their needs in order to increase their awareness of DM medication. [21]

References

1. American Diabetes Association. 2 Classification and diagnosis of diabetes: standards of medical care in .diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S13–28
2. Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes and pregnancy. Can J .Diabetes. 2018;42(Suppl 1):S255–S282282
3. Noctor E, Crowe C, Carmody LA, et al. Abnormal glucose tolerance post-gestational diabetes mellitus as defined by the International Association of Diabetes and Pregnancy Study Groups criteria. Eur J Endocrinol. 2016;175(4):287–97
4. Williams R, Colagiuri S, Almutairi R, et al. IDF Diabetes Atlas. 9th ed. International Diabetes .Federation; 2019
5. Siegel KR, Patel SA, Ali MK. Non-communicable diseases in South Asia: contemporary perspectives. . [Br Med Bull. 2014;111(1):31–44. doi: 10.1093/bmb/ldu018
6. Putri SMNK, Christina M, Saverinus S, Halimatunnisa H, Susanti S. Factors associated with obesity in . [adults in South East Asia. Int J Psychosoc Rehabilitation. 2020;24(7):54
7. Low WY, Lee YK, Samy AL. Non-communicable diseases in the Asia-Pacific region: prevalence, risk . [factors and community-based prevention. IJOMEH. 2014;28(1). doi: 10.2478/s13382-014-0326-0

8. Gupta Y, Goyal A, Kalra S, Tandon N. Variation in the classification of hyperglycaemia in pregnancy .and its implication. Lancet Diabetes Endocrinol. 2020;8(4):264–6
9. Mannava P, Abdullah A, James C, Dodd R, Annear PL. Health systems and noncommunicable diseases . in the Asia-Pacific Region: a review of the published literature. Asia Pac J Public Health. 2015;27(2):NP1– [NP19. doi: 10.1177/1010539513500336
10. Chaudhury A, Duvoor C, Reddy Dendi VS, et al. Clinical review of antidiabetic drugs: implications for . type 2 diabetes mellitus management. Front Endocrinol. 2017;8(JAN). doi: 10.3389/fendo.2017.00006
11. Verhulst MJL, Loos BG, Gerdes VEA, Teeuw WJ. Evaluating all potential oral complications of . [diabetes mellitus. Front Endocrinol (Lausanne). 2019;10(56). doi: 10.3389/fendo.2019.00056
12. Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and . decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res. 2012;12(1):1. doi:
13. Venkatesan R, Devi AM, Parasuraman S, et al. (2012) Role of community pharmacists in improving knowledge and glycemic control of type 2 diabetes. Perspectives in Clinical Research 3(1): 26–31.
14. Winters A, Esse T, Bhansali A, Serna O, Mhatre S, Sansgiry S. Physician perception of patient . medication adherence in a cohort of medicare advantage plans in Texas. J Manag Care Spec Pharm. [2016;22(3):305–312. doi: 10.18553/jmcp.2016.22.3.305
15. Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people . [with type 2 diabetes. Diabetes Care. 2012;35(6):1279–1284. doi: 10.2337/dc11-1277
16. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: truth and . consequences. Am J Med Sci. 2016;351(4):387–399. doi: 10.1016/j.amjms.2016.01.010
17. Chaudhury A, Duvoor C, Reddy Dendi VS, et al. Clinical review of antidiabetic drugs: implications for . type 2 diabetes mellitus management. Front Endocrinol. 2017;8(JAN). doi:10.3389/fendo.2017.00006
18. Verhulst MJL, Loos BG, Gerdes VEA, Teeuw WJ. Evaluating all potential oral complications of . .(diabetes mellitus. Front Endocrinol (Lausanne
doi:10.3389/fendo.2019.00056 .(56)10;2019
19. Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res. 2012;12(1):1. doi:10.1186/1472-6963-12-270
20. Winters A, Esse T, Bhansali A, Serna O, Mhatre S, Sansgiry S. Physician perception of patient . medication adherence in a cohort of medicare advantage plans in Texas. J Manag Care Spec Pharm. 2016;22(3):305–312. doi:10.18553/jmcp.2016.22.3.305
21. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: truth and . consequences. Am J Med Sci. 2016;351(4):387–39